(Paris:IPN), Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo(R), Bylvay(R) and Somatuline(R) Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosion of Somatuline(R) and accelerated sales growth of the rest of the portfolio: total sales […]
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance GlobeNewswire October 22, 2025 Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo(R), Bylvay(R) and Somatuline(R) Further upgrade of full-year 2025 financial guidance
(TSX:TECK.A),(TSX:TECK.B),(TSX:TECK-A),(TSX:TECK-B),(NYSE:TECK), VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited third quarter results for 2025. “The merger of equals between Teck and Anglo American announced this quarter is a unique opportunity to create a global leader in critical minerals and a
Teck Reports Unaudited Third Quarter Results for 2025 Merger of equals to create new global critical minerals champion and unlock substantial value GlobeNewswire October 22, 2025 VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited third quarter results for 2025. “The
Studio Blue sets new benchmarks for game audio production Ubisoft Singapore, a leading AAA game development studio in Southeast Asia, has recently outfitted its newly upgraded Studio Blue with Neumann studio monitors which belongs to Sennheiser Group to support advanced audio production workflows. As the first Dolby Atmos-enabled game development sound studio in Southeast Asia,
(Paris:IPN), Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire
(Paris:SAN), Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels
Munich, 22.10.2025 – A2MAC1 and ZeBeyond announce a strategic collaboration that introduces a simulation-first benchmarking platform for electric powertrains. The new approach enables OEMs and Tier 1 suppliers to validate vehicle efficiency and performance within days – compared to traditional teardown and dynamometer testing that can take more than a year. As automakers race to
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline GlobeNewswire October 22, 2025 Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in
A2MAC1 and ZeBeyond partner to bring Simulation-First Powertrain Benchmarking to market GlobeNewswire October 22, 2025 Munich, 22.10.2025 – A2MAC1 and ZeBeyond announce a strategic collaboration that introduces a simulation-first benchmarking platform for electric powertrains. The new approach enables OEMs and Tier 1 suppliers to validate vehicle efficiency and performance within days – compared to traditional